Navigation Links
Researchers challenge previous findings regarding widely used asthma treatment
Date:1/10/2008

WINSTON-SALEM, N.C. A new study published recently in The Lancet reveals that one of the most commonly used asthma medicines -- long-acting beta-agonists -- may not be associated with adverse events in people based on their genotype (gene variation), as previous studies had shown.

The study analyzed the effects of long-acting beta-agonist therapy, used in combination with inhaled corticosteroids, in asthmatics who have a specific beta-2 adrenergic receptor (ADRB2) genotype.

Investigators analyzed data from two clinical trials performed by AstraZeneca Pharmaceuticals LP. In each trial, patients were randomized to receive one of two different long-acting beta-agonists. In the case of each of the therapies, asthma symptoms and control improved, but no differences were observed based on the ADRB2 genotype.

These results are extremely important because previous studies on short-acting beta-agonists showed evidence for an adverse genotypic effect, said Eugene R. Bleecker, M.D., Thomas H. Davis Professor of Medicine, co-director of Center for Human Genomics at Wake Forest Baptist, and lead-investigator for the study. Smaller studies on long-acting beta-agonists have produced conflicting results.

Current guidelines recommend the use of combination therapy, with long-acting beta-agonists and inhaled corticosteroids, to control moderate to severe persistent asthma.

With over 2,000 patients in this study receiving combination therapy, it was reassuring that no adverse safety effects could be attributed to an individuals genotype, said Bleecker.

Ten percent of the U.S. population suffers from asthma. Each year, approximately 4,000 people die with asthma as the underlying cause.


'/>"/>

Contact: Shannon Koontz
shkoontz@wfubmc.edu
336-716-2415
Wake Forest University Baptist Medical Center
Source:Eurekalert

Page: 1

Related medicine news :

1. UT Health Science Center researchers decoding saliva to detect breast cancer
2. Protein power: Researchers trigger insulin production in diabetic mice
3. Researchers use neuroimaging to study ESP
4. UGA researchers receive $9 million in grants to study barriers to effective addiction treatment
5. Researchers seek to make cavity-causing bacteria self-destruct
6. Human factors researchers test voting systems for seniors that can improve voting accuracy and speed
7. New research tools are too complex for easy answers, researchers say
8. In largest U.S. Hep C trial, researchers determine weight-based dosing is key to optimal treatment
9. U of M researchers discover fast-acting cyanide antidote
10. SLU researchers show how to stop muscle weakness caused by myasthenia gravis
11. Researchers solve first structure of a key to intact DNA inheritance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... Nevada (PRWEB) , ... October 13, 2017 , ... ... Hemp CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil ... required and providing a CBD form that can be easily incorporated into liquid products, ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that covers care ... have a waiver for care if the client has a cognitive impairment diagnosis. ... for care, is often waived, so the benefits from their insurance start immediately,” said ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer ... one of the most popular and least understood books in the Holy Scriptures, Revelation. ... descriptions that have baffled scholars for centuries. Many have tossed it off as mere ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... “America On ... Christian identity. “America On The Brink” is the creation of published author, William ... several great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... to meet the demand of today’s consumer and regulatory authorities worldwide. From Children’s ... experts and tested to meet the highest standard. , These products are ...
Breaking Medicine News(10 mins):
(Date:9/12/2017)... PARIS and NEW YORK , Sept. 12, ... ethical performance ratings for global supply chains, has published the first annual ... the CSR performance of more than 20,400 companies evaluated by EcoVadis, based ... years 2015 and 2016. ... EcoVadis Global CSR Risk & Performance Index ...
(Date:9/12/2017)... SAN FRANCISCO , Sept. 12, 2017 /PRNewswire/ ... Lifecycle Management Solutions (VLMS), is pleased to announce ... as a member of its Board of Directors ... 2017. ValGenesis VLMS enables life science companies to ... eliminate the use of paper in this process. ...
(Date:9/9/2017)... Dealmed Medical Supplies, New York ... supplies, drugs, vaccines, and specialty medical products and services, ... to acquire Vantage Medical Supplies, a major distributor of ... New York . ... medical practices, will operate under the Dealmed name as ...
Breaking Medicine Technology: